̈ Record quarterly sales orders of $22.4M (TCV1) in Q2 FY23; up...

• ̈ Record quarterly sales orders of $22.4M (TCV1) in Q2 FY23; up 280% on $5.9M in Q2 FY22 (or up 240% on $6.6M in constant currency2)

• ̈ Record revenue of $18.1M in H1 FY23; up 27% on $14.3M in H1 FY22; positive EBITDA

• ̈ Contracted Annual Recurring Revenue (CARR) of $20.0M; ($17.9M at 30 Sept 2022)

• ̈ Annual Recurring Revenue (ARR) run rate of $16.4M; ($15.5M at 30 Sept 2022)

• ̈ Increased exposure to high growth radiology outpatient market with new customers Nuvodia

  and Akumin

• ̈ Cash on hand $20.6M; ($21.5M at 30 Sept 2022 )

Another good quarter appears to be driven by strong health industry desire to integrate tech into business models.

on track for continued growth this year and into the future. Continued contract revenue growth builds the base and improves efficiency. Closer to full year EBITDA positive. Great news for long term investors.

All IMO DYOR